The findings of a 20-year
study recently published in the British journal The Lancet (Vol.
354, No. 9,190) confirm that women who undergo in-vitro fertilization (IVF)
have no greater risk of developing invasive breast, uterine, or ovarian
cancers than women who do not undergo the procedure.
In-vitro fertilization involves removing eggs from the uterus and placing
them in a laboratory dish, where they are fertilized by sperm before being
returned to the woman's uterus. Women undergoing IVF are given hormones
to boost ovulation, and there has been concern over whether the hormones
increase the risk of certain cancers.
The study analyzed data on 29,700 women provided by 10 clinics over
the course of 22 years, making this the largest research project of its
type ever conducted. Of the study group, 20,656 women were exposed to fertility
drugs, and 9,044 were not. The exposed group showed no greater rates of
breast or ovarian cancer than was expected of the general population.
Researchers expected to find 155 cases of breast cancer and found 143.
They predicted and found 13 cases of invasive ovarian cancer.
Invasive ovarian cancer is the most common form of ovarian cancer. This
study did not determine whether fertility drugs affected the women's risk
of developing ovarian tumors of low malignant potential. These tumors,
also known as borderline tumors, have been linked to fertility drug use
in some, but not all, earlier studies. Borderline tumors tend to spread
within the pelvis and abdomen. However, they do not spread through the
bloodstream as often as invasive ovarian cancers. Although borderline tumors
tend to have a better prognosis than invasive cancers, some cases may be
fatal.
The study also suggested there is an increased risk of cancer in very
small sub-groups of women. Women with unexplained infertility had significantly
more cancers of the ovary and uterus than expected, whether or not they
had taken fertility drugs. Also, more cases of breast cancer were diagnosed
in the first year after treatment with fertility drugs than researchers
predicted: nine were predicted and 17 were detected.
Alison Venn, PhD, an epidemiologist at La Trobe University in Melbourne,
Australia, and lead author of the study, speculated that the higher number
of breast cancer diagnoses within a year after fertility treatment might
be due to increased medical supervision for those women at that time rather
than an increase in cancer cases. It might also be that hormonal changes
as a result of pregnancy or fertility treatment could stimulate the growth
of existing tumors, though they wouldn’t cause the cancer. "You can’t cause
breast cancer that quickly," Dr. Venn said.
As for why women with unexplained infertility had higher-than-expected
rates of ovarian and uterine cancer, Dr. Venn believes, in some of these
women, infertility might have been a symptom when the underlying disease
was cancer.
Debbie Saslow, PhD, director of breast and cervical cancer for the American
Cancer Society (ACS), agreed with that assessment. "The reason for infertility
might be the same as what is causing women to develop ovarian cancer,"
she said. "A great deal depends on how much estrogen a woman has been exposed
to. All of this is clearly related to hormones, but more research is needed
to understand the mechanisms involved."
Dr. Venn said the women in the study should be followed as they grow
older to try to understand the reasons for increased risk of certain cancers
in women with unexplained infertility.
ACS News Center stories are provided as a source of cancer-related
news and are not intended to be used as
press releases.
|